Last updated: 2 months ago
Dynavax Technologies Q4 2024 Financial Report: Strong Recovery & Buy Recommendation
Discover Dynavax Technologies' impressive Q4 2024 financial performance, featuring revenue growth, profitability, and a buy recommendation. Key insights into HEPLISAV-B's impact.